# CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases

> **NCT05827835** · PHASE1,PHASE2 · RECRUITING · sponsor: **Zhejiang University** · enrollment: 30 (estimated)

## Conditions studied

- Hematologic Diseases
- Neoplasms

## Interventions

- **DRUG:** CD7 CAR-T cells injection
- **OTHER:** Allogeneic hematopoietic stem cell transplantation

## Key facts

- **NCT ID:** NCT05827835
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-30
- **Primary completion:** 2026-04-25
- **Final completion:** 2027-04-25
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-08-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05827835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05827835, "CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05827835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*